BioCardia CEO buys 2,300 shares in open market

BioCardia, Inc. President and CEO Peter Altman reported open-market purchases of the company’s Common Stock.

Rhea-AI Filing Summary

BioCardia, Inc. President and CEO Peter Altman reported open-market purchases of the company’s Common Stock. On June 17, 2026, he bought 1,500 shares at a weighted average price of $0.85 per share. On June 18, 2026, he bought an additional 800 shares at a weighted average price of $0.96 per share. Following these transactions, Altman directly owns 300,566 shares of BioCardia Common Stock.

Insider Trade Summary

Net Buyer: 2,300 shares

Net Buy 2 txns

Insider Altman Peter

Role President and CEO

Bought 2,300 shs ($2K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	800	$0.96	$768.00
Purchase	Common Stock	1,500	$0.85	$1K

Holdings After Transaction: Common Stock — 300,566 shares (Direct)

Footnotes (2)

1. F1. This transaction was executed in multiple trades ranging from $0.84 to $0.89 per share. The price reported above reflects the weighted average per share sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer, full information regarding the number shares purchased at each separate price.
2. F2. This transaction was executed in multiple trades ranging from $0.98 to $0.96 per share. The price reported above reflects the weighted average per share sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer, full information regarding the number shares purchased at each separate price.

Key Figures

Shares bought June 17, 2026: 1,500 shares Price June 17, 2026: $0.85 per share Shares bought June 18, 2026: 800 shares +3 more

6 metrics

Shares bought June 17, 2026 1,500 shares Open-market purchase at weighted average $0.85 per share

Price June 17, 2026 $0.85 per share Weighted average purchase price for 1,500 shares

Shares bought June 18, 2026 800 shares Open-market purchase at weighted average $0.96 per share

Price June 18, 2026 $0.96 per share Weighted average purchase price for 800 shares

Shares owned after trades 300,566 shares Common Stock directly owned after June 18, 2026 transaction

Total shares bought 2,300 shares Sum of open-market purchases on June 17 and 18, 2026

Key Terms

open-market purchase, Common Stock, weighted average per share sales price, directly owns

4 terms

open-market purchase financial

"he bought 1,500 shares at a weighted average price of $0.85 per share"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

Common Stock financial

"open-market purchases of the company’s Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

weighted average per share sales price financial

"The price reported above reflects the weighted average per share sales price"

directly owns financial

"Following these transactions, Altman directly owns 300,566 shares"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did BioCardia (BCDA) report in this Form 4?

BioCardia reported that President and CEO Peter Altman made two open-market purchases of Common Stock, totaling 2,300 shares, on June 17 and June 18, 2026. These transactions increased his directly held position in the company.

How many BioCardia (BCDA) shares did the CEO buy and at what prices?

Peter Altman purchased 1,500 BioCardia Common Stock shares at a weighted average price of $0.85 on June 17, 2026, and 800 shares at a weighted average price of $0.96 on June 18, 2026, through open-market transactions.

What is Peter Altman’s total BioCardia (BCDA) shareholding after these trades?

After the reported open-market purchases, President and CEO Peter Altman directly owns 300,566 shares of BioCardia Common Stock. This figure reflects his position immediately following the June 18, 2026 transaction disclosed in the Form 4.

Were BioCardia (BCDA) CEO share purchases executed in multiple trades?

Yes. Footnotes state each transaction was executed in multiple trades within price ranges of $0.84–$0.89 and $0.96–$0.98 per share. The reported prices represent weighted averages across those individual trades on each respective day.

Are the BioCardia (BCDA) CEO’s transactions direct or indirect holdings?

The Form 4 identifies Peter Altman’s ownership as direct for these transactions. The reported 300,566 shares of BioCardia Common Stock are held directly by him, with no indication of intermediary entities such as trusts or family partnerships.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/22/2026 - 06:09 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Altman Peter

(Last) (First) (Middle)

C/O BIOCARDIA, INC.

320 SOQUEL WAY

(Street)

SUNNYVALE CALIFORNIA 94085

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BioCardia, Inc. [ BCDA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/17/2026		P		1,500(1)	A	$0.85(1)	299,766	D
Common Stock	06/18/2026		P		800(2)	A	$0.96(2)	300,566	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed in multiple trades ranging from $0.84 to $0.89 per share. The price reported above reflects the weighted average per share sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer, full information regarding the number shares purchased at each separate price.

2. This transaction was executed in multiple trades ranging from $0.98 to $0.96 per share. The price reported above reflects the weighted average per share sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer, full information regarding the number shares purchased at each separate price.

	/s/ David McClung, by power of attorney	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)